Human papillomavirus vaccine recombinant quadrivalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Merck

Alternative Names: Gardasil; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Merck; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Merck; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Merck; Quadrivalent human papillomavirus vaccine - Merck; Silgard; V 501

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator CSL; The University of Queensland
  • Developer Banyu; CSL; Merck & Co; Merck Sharp & Dohme; University of California at San Francisco
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Gynaecological cancer; Human papillomavirus infections
  • Phase III Condylomata acuminata; Penile cancer

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Sep 2016 Merck completes a phase III trial in for Human papillomavirus/Cervical cancer in China (NCT00834106)
  • 01 Nov 2015 Phase-III clinical trials in Human papillomavirus infections (In children, In adolescents, In volunteers) in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top